EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi and Submits Market…
Posted: October 25, 2020 at 5:55 am
Oct. 21, 2020 11:00 UTC
FREIENBACH, Switzerland--(BUSINESS WIRE)-- EffRxSA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, a specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, for the registration and commercialization of Alkindi for pediatric adrenocortical insufficiency (AI) in Switzerland. Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Alkindi in Switzerland.
Alkindi is the first preparation of hydrocortisone specifically designed for use in children suffering from paediatric adrenocortical insufficiency (AI). Alkindi is a patented, oral, immediate-release paediatric formulation of hydrocortisone granules in capsules for opening that allows for accurate age-appropriate dosing in children. This therapeutic approach has the potential to help young patients less than eighteen years of age suffering from pediatric AI and the related condition congenital adrenal hyperplasia (CAH).
Alkindi is already approved and marketed in the European Union and is the first preparation of hydrocortisone specifically designed for use in children suffering from AI. On September 29th, 2020 the US Food and Drug Administration (FDA) has also approved Alkindi for AI.
EffRx has recently submitted to Swissmedic (Switzerland) a Market Authorization Application for the registration of Alkindi. Pending successful regulatory registration, this new treatment approach is expected to be available on the Swiss market by 2022. In Switzerland there are approximately 200 patients suffering from pediatric AI.
We are extremely pleased to announce this partnership with Diurnal which demonstrates EffRx capability to expand its portfolio with promising niche and orphan medicines, commented Lorenzo Bosisio, CEO of EffRx Pharmaceuticals. We look forward to bringing this novel therapeutic approach to Switzerland. We are confident that Alkindi provides a tangible advancement for young patients suffering from AI and their carers.
Martin Whitaker, CEO of Diurnal, commented: This partnership with EffRx further validates the quality of our products and broadens the future availability of Alkindi. EffRx is well-placed to register and market our product Alkindi in Switzerland. We have made strong progress with the sales of Alkindi across Europe since its approval and subsequent launch in 2018, and we are confident this agreement will enable further growth.
Pediatric AI, including the genetic condition CAH is a condition characterised by deficiency in cortisol, an essential hormone in regulating metabolism and the response to stress. The primary symptoms of AI are chronic fatigue and patients are at risk of adrenal crisis and death if they do not have adequate cortisol replacement. AI is either primary or secondary, with primary AI resulting from diseases intrinsic to the adrenal gland and secondary AI resulting from pituitary diseases where there is a failure of stimulation of the adrenal by the pituitary of the signalling hormone ACTH (adrenocorticotropic hormone).
About EffRx Pharmaceuticals
EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.
EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from the FDA for a pipeline asset.
EffRxs go-to-market competence is proven by the development, launch and lucrative expansion of Binosto in a highly competitive European market. Our lead commercialized product, Binosto for the treatment of osteoporosis, is marketed in the US as well as selected European and Asian countries.
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-headquartered, European specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit http://www.diurnal.co.uk
View source version on businesswire.com: https://www.businesswire.com/news/home/20201021005435/en/
- Immunosenescence Profile and Expression of the Aging Biomarker (p16INK4a) in Testicular Cancer Survivors Tr... - UroToday - February 11th, 2021
- Europe to hold The major Piece of Cake in the Anabolic Steroids Market between 2020 and 2030 Jumbo News - Jumbo News - February 11th, 2021
- The Male Hypogonadism Market to witness a splendid CAGR in the next decade Murphy's Hockey Law - Murphy's Hockey Law - February 3rd, 2021
- Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha... - UroToday - February 3rd, 2021
- Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX... - January 29th, 2021
- Male Hormone Replacement Therapy And The Side Effects - Nerd's Magazine - January 29th, 2021
- New York Medical and Life Sciences: Year in Review 2020 - JD Supra - January 29th, 2021
- Male menopause: symptoms, diagnosis and treatment - Netdoctor - January 29th, 2021
- Freeman: 'Pressure to Succeed' Led to Testosterone Order - Medscape - January 27th, 2021
- Hormone Replacement Therapy Market Growth Analysis,Size,Insight,Share And Outlook By 2027 Pfizer, AbbVie, Novo Nordisk NeighborWebSJ - NeighborWebSJ - January 27th, 2021
- Male Hypogonadism Therapy Market to Witness Massive Growth During 2021-2027 | Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - January 25th, 2021
- Male Hypogonadism Therapy Market and Ecosystem by Production, Prospects, Consumption, Cost Structure, Competitive Landscape - Jumbo News - January 25th, 2021
- What is Harvey Prices disability Prader-Willi Syndrome? - The Sun - January 25th, 2021
- The Male Hypogonadism Market To Witness An Escalating CAGR Of 3.7% - NeighborWebSJ - January 19th, 2021
- Androgen Replacement Therapy Market to Witness Robust Expansion throughout the Forecast Period 2017-2026 | AbbVie, Inc., Allergan Plc, Bayer AG, Endo... - January 19th, 2021
- Global COVID-19 Diagnostics Market Size Worth USD 11.40 Billion at 7.9% CAGR; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for... - January 19th, 2021
- Marius Pharmaceuticals Submits New Drug Application to US FDA for Next-Generation Oral Testosterone Replacement Therapy in Male Patients With... - January 12th, 2021
- Testosterone Replacement Therapy Market (2020 2027) Explosive Factors of Revenue by Key Manufacturer, Share, Future Trends, COVID-19 Market Scenario,... - January 9th, 2021
- The Anabolic Steroids Market to sharpen in the next decade - The Monitor - January 9th, 2021
- Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report - DocWire News - December 24th, 2020
- Male Hypogonadism Therapy Market Detailed Analysis Of Current Industry Figures With Forecasts Growth By 2026 - Cheshire Media - December 6th, 2020
- Male Hypogonadism Market is Expected to Thrive at Impressive CAGR by 2026 & Top Key Players are Astrazeneca Plc., Merck& Co. Inc.,... - December 6th, 2020
- Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for M... - UroToday - December 6th, 2020
- Prader-Willi Syndrome Facts: Causes, Diagnosis, Treatments and Prognosis - Gilmore Health News - December 6th, 2020
- Male Hypogonadism HRT Treatment Market 2020-28 booming segments, latest trends and analysis with Merck & Co, Allergan, Endo International,... - December 6th, 2020
- MLB notebook: Red Sox, Rodriguez agree to one-year, $8.3 million deal to avoid arbitration - pressherald.com - December 6th, 2020
- Impact of Covid-19 on Testosterone undecanoate Market is slated to grow rapidly in the forthcoming years with Key Players Bayer AG, Endo... - November 28th, 2020
- Estrogen in men: Symptoms of high and low levels, and more - Medical News Today - November 11th, 2020
- Aytu BioScience to Present at the Jefferies 2020 Virtual London Healthcare Conference Wednesday, November 18 at 1:45pm ET - Stockhouse - November 11th, 2020
- Global Testosterone Replacement Therapy Market 2020 : Industry Analysis by Top Countries Data Definition, Size, Share, Segmentation and Forecast data... - November 11th, 2020
- Male Hypogonadism Therapy Market Forecast to 2027: Top Companies, Trends & Growth Factors and Trend Forecast to 2027 - TechnoWeekly - November 5th, 2020
- The Male Hypogonadism Market To Slither Amidst Covid-19, To Pick Up Pace Post-Covid-19, Reach US$ 3300 Mn - The Think Curiouser - November 5th, 2020
- Global Hypogonadism Drug Market Business Share, Industry Size and Future Investment Opportunities by 2026||ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly... - November 5th, 2020
- Aytu BioScience to Report First Quarter Fiscal 2021 Results and Provide Business Update on Thursday, November 12, 2020 - Press Release - Digital... - November 5th, 2020
- Global Hormone Replacement Therapy Market Recent Trends, Development, Growth and Forecast 2020-2027 - Eurowire - November 5th, 2020
- Andropause: Not the same as menopause but needs to be addressed - The Star Online - October 28th, 2020
- Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) for the... - October 28th, 2020
- Hormone Replacement Drugs Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2026|Eli Lilly, Pfizer, AbbVie - Eurowire - October 28th, 2020
- The Anabolic Steroids market to go the reverse transversal way in the next decade - The Think Curiouser - October 25th, 2020
- Male Hypogonadism Therapy Market is Booming Worldwide By Top Key Players: Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - October 13th, 2020
- Hormone Replacement Therapy Market Size, Trends, Growth, Key Companies, Forecast by 2026|Eli Lilly, Pfizer, AbbVie - Weekly Wall - October 13th, 2020
- Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year - BioSpace - October 10th, 2020
- Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020 - Yahoo Finance - October 10th, 2020
- Sperm Take Up to 3 Years to Recover After Anabolic Steroids - Medscape - October 4th, 2020
- Covid-19 could lower testosterone levels and libido in men - heres what the new study found - Shields Gazette - October 4th, 2020
- Testosterone Replacement Therapy Market 2020 Global Industry Sales, Industry Analysis with Top Countries Data, Share, Trends, Market Demand, Revenue,... - October 4th, 2020
- Treatment of the infertile couple - Contemporary Obgyn - October 4th, 2020
- Testosterone boosters: Uses and effectiveness - Medical News Today - September 22nd, 2020
- Aytu BioScience to Report Fourth Quarter FY 2020 Results and Business Update on Thursday, September 24, 2020 - Yahoo Finance - September 18th, 2020
- H.C. Wainwright Reiterated Lipocine Inc. [LPCN]. What else is Wall St. saying? - The DBT News - September 3rd, 2020
- Hormone Replacement Therapy Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the... - September 3rd, 2020
- Male Hypogonadism Market Estimated to be Driven by Innovation and Industrialization 2017 2026 - The News Brok - August 24th, 2020
- Male Hypogonadism Therapy Industry 2020 Market Size, Share, Price, Trend And Forecast To 2026- Industry Growth Insights - The Scarlet - August 24th, 2020
- Male Hypogonadism Market : Extensive Analysis of Key Segments of the Industry and Emerging Growth Factors with Current Trends and Future Estimations -... - August 24th, 2020
- COVID-19 Impact On Hormone Replacement Therapy Market Size, Status And Forecast 2020-2026 - Galus Australis - August 14th, 2020
- Male Hypogonadism Therapy Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and Forecast to 2027... - August 13th, 2020
- UB study finds testosterone therapy can lead to remission in men with Type 2 diabetes - UB Now: News and views for UB faculty and staff - University... - August 5th, 2020
- Male Hypogonadism Market 10-Year Market Forecast and Trends Analysis Research Report2017 2026 - The Daily Chronicle - August 4th, 2020
- UB diabetes expert's research shows testosterone therapy can lead to remission in men with Type 2 diabetes - UB News Center - July 31st, 2020
- Hormon replacement therapy Market Growth, Opportunities and Updated Business Strategies|Bayer Pharma - PharmiWeb.com - July 31st, 2020
- What are COVID-19 Impact on Male Hypogonadism Market? & what are Major Drives Which Boost Market Even In Outbreak? - WOLE TV - July 31st, 2020
- Testosterone Replacement Therapy and Its Potential Mental Health Benefits to Men - Press Release - Digital Journal - July 31st, 2020
- Global Testosterone Cypionate Market (Covid-19 Impact) Expected to Witness a Sustainable Growth over 2026 - Market Research Correspondent - July 31st, 2020
- Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration - BioSpace - July 31st, 2020
- What is Male Menopause? Heres everything you need to know about andropause - PINKVILLA - July 26th, 2020
- North America Hormone Replacement Therapy Market: Demand, Share, Size, Industry Trends, Analysis and Forecast during 2020-2025 - Jewish Life News - July 3rd, 2020
- North America Hormone Replacement Therapy Market: Share, Industry Trends, Price, Size, Demand and Forecast to 2020-2025 - 3rd Watch News - July 3rd, 2020
- Testosterone undecanoate Market 2020 | What Will Be the Market Size and the Growth Rate Analysis by 2025? - Cole of Duty - July 1st, 2020
- Advancements in treatments in healthcare is boosting the Human Chorionic Gonadotropin (HCG) Market - Day Web Chronicle - July 1st, 2020
- Global Hormone Replacement Therapy Market 2020 Research by Business Analysis, Growth Strategy and Industry Development to 2025 - Cole of Duty - July 1st, 2020
- No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn - The Gardner News - June 22nd, 2020
- Human Chorionic Gonadotropin (hCG) Market Insights on Growth Trends, Top Players, Types, Applications and Regional Analysis - Personal Injury Bureau... - June 22nd, 2020
- Male Hypogonadism Therapy Market Research Growth by Manufacturers, Regions, Type and Application, Forecast Analysis to 2026 - CueReport - June 20th, 2020
- Emerging Opportunity in Transdermal Testosterone Market with Eminent Key Players and Future Outlook to 2024: AbbVie, Teva, Perrigo, Endo... - June 20th, 2020
- No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn - Lexington Dispatch - June 20th, 2020
- Testosterone Gel Market: 2020 Industry Trends, Size, Growth Predictions, Segmentation, Business Statistics, Top Key Players and 2026 Forecast Research... - June 18th, 2020
- Anabolic Steroids Market to Witness Heightened Revenue Growth in the Next Decade - Owned - June 18th, 2020
- Male Hypogonadism Therapy Market Business Analysis 2020 by Leading Industrial Source, Statistics, Gross Margin, Upstream Analysis, Downstream Analysis... - June 14th, 2020
- QOL and body composition benefits seen with novel oral T treatment - Urology Times - June 14th, 2020
- Novel oral testosterone therapy shows liver health benefits - Urology Times - June 14th, 2020